2024
Hepatitis Delta Virus Testing, Prevalence, and Liver-Related Outcomes Among U.S. Veterans with Chronic Hepatitis B
Wong R, Yang Z, Jou J, John B, Lim J, Cheung R. Hepatitis Delta Virus Testing, Prevalence, and Liver-Related Outcomes Among U.S. Veterans with Chronic Hepatitis B. Gastro Hep Advances 2024 DOI: 10.1016/j.gastha.2024.10.015.Peer-Reviewed Original ResearchChronic hepatitis B patientsChronic hepatitis BLiver-related outcomesHepatic decompensationHepatitis delta virusCohort of U.S. veteransNational cohortU.S. veteransRisk of cirrhosisIncidence of cirrhosisPositive patientsHDV infectionHepatitis BEvaluate incidenceHepatocellular carcinomaCirrhosisPatientsDecompensationVirus testingPropensity scoreHepatitisDelta virusNelson-Aalen methodDiagnosisOutcomesFRI-389 Hepatitis delta virus infection is associated with significantly greater incidence of cirrhosis and hepatic decompensation in U.S. veterans with chronic hepatitis B
Wong R, Yang Z, Jou J, John B, Lim J, Cheung R. FRI-389 Hepatitis delta virus infection is associated with significantly greater incidence of cirrhosis and hepatic decompensation in U.S. veterans with chronic hepatitis B. Journal Of Hepatology 2024, 80: s771. DOI: 10.1016/s0168-8278(24)02152-4.Peer-Reviewed Original Research
2023
Screening, Diagnosis, and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD): Application of Society Guidelines to Clinical Practice
Ilagan-Ying Y, Banini B, Do A, Lam R, Lim J. Screening, Diagnosis, and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD): Application of Society Guidelines to Clinical Practice. Current Gastroenterology Reports 2023, 25: 213-224. PMID: 37768417, DOI: 10.1007/s11894-023-00883-8.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNon-alcoholic fatty liver diseaseNon-invasive testsFatty liver diseaseLiver diseaseCommon chronic liver diseaseNonalcoholic fatty liver diseaseCurrent expert guidelinesHigh-risk patientsChronic liver diseaseSteatotic liver diseaseClinical practice implicationsHepatic decompensationLiver biopsySociety guidelinesSpecialty referralsNovel therapiesExpert guidelinesLiver cancerDisease awarenessObesity epidemicSerum indicesClinical practiceScreening toolDiseaseDiagnosis
2015
Entecavir safety and effectiveness in a national cohort of treatment‐naïve chronic hepatitis B patients in the US – the ENUMERATE study
Ahn J, Lee HM, Lim JK, Pan CQ, Nguyen MH, Kim W, Mannalithara A, Trinh H, Chu D, Tran T, Min A, Do S, Te H, Reddy KR, Lok AS. Entecavir safety and effectiveness in a national cohort of treatment‐naïve chronic hepatitis B patients in the US – the ENUMERATE study. Alimentary Pharmacology & Therapeutics 2015, 43: 134-144. PMID: 26510638, PMCID: PMC4926997, DOI: 10.1111/apt.13440.Peer-Reviewed Original ResearchConceptsALT normalisationAdverse eventsHBV DNAHBeAg(-) patientsHBV patientsTreatment-naïve chronic hepatitis B patientsChronic hepatitis B patientsFive-year cumulative probabilityHBsAg loss/seroconversionLog 10 IU/Hepatitis B virus infectionEffectiveness of entecavirMedian HBV DNAUndetectable HBV DNAHepatitis B patientsB virus infectionAbnormal ALTEntecavir treatmentETV treatmentHBeAg lossHBsAg lossHepatic decompensationB patientsCohort studyMedian duration